header image

Page 70«..1020..69707172..8090..»

Archive for Pet Stem Cell Therapy

iPS Cell-based Neuron Therapy Benefits Monkeys With Parkinson’s – ReliaWire

Monkeys with Parkinsons disease symptoms show significant improvement over two years after being transplanted neurons prepared from human induced pluropontent stem cells, scientists at the Center for iPS Cell Research and Application (CiRA), Kyoto University, report. One of the last steps before treating patients with an experimental cell therapy for the brain is confirmation that the therapy works in monkeys.

Parkinsons disease degenerates a specific type of cells in the brain known as dopaminergic (DA) neurons. It has been reported that when symptoms are first detected, a patient will have already lost more than half of his or her DA neurons.

Several studies have shown the transplantation of DA neurons made from fetal cells can mitigate the disease.

The use of fetal tissues is controversial, however. On the other hand, iPS cells can be made from blood or skin.

Our research has shown that DA neurons made from iPS cells are just as good as DA neurons made from fetal midbrain. Because iPS cells are easy to obtain, we can standardize them to only use the best iPS cells for therapy,

said Professor Jun Takahashi, a neurosurgeon specializing in Parkinsons disease, who plans to use DA neurons made from iPS cells to treat patients.

To test the safety and effectiveness of DA neurons made from human iPS cells, Tetsuhiro Kikuchi, a neurosurgeon working in the Takahashi lab, transplanted the cells into the brains of monkeys.

We made DA neurons from different iPS cells lines. Some were made with iPS cells from healthy donors. Others were made from Parkinsons disease patients,

said Kikuchi, who added that the differentiation method used to convert iPS cells into neurons is suitable for clinical trials.

It is generally assumed that the outcome of a cell therapy will depend on the number of transplanted cells that survive, but Kikuchi found this was not the case. More important than the number of cells was the quality of the cells.

Each animal received cells prepared from a different iPS cell donor. We found the quality of donor cells had a large effect on the DA neuron survival, Kikuchi said.

To understand why, he looked for genes that showed different expression levels, finding 11 genes that could mark the quality of the progenitors. One of those genes was Dlk1.

Dlk1 is one of the predictive markers of cell quality for DA neurons made from embryonic stem cells and transplanted into rat. We found Dlk1 in DA neurons transplanted into monkey. We are investigating Dlk1 to evaluate the quality of the cells for clinical applications.

Another feature of the study that is expected to extend to clinical study is the method used to evaluate cell survival in the host brains. The study demonstrated that magnetic resonance imaging (MRI) and position electron tomography (PET) are options for evaluating the patient post surgery.

MRI and PET are non-invasive imaging modalities. Following cell transplantation, we must regularly observe the patient. A non-invasive method is preferred,

said Takahashi.

The group is hopeful that it can begin recruiting patients for this iPS cell-based therapy before the end of next year. The study is the teams answer to bring iPS cells to clinical settings, said Takahashi.

Tetsuhiro Kikuchi, Asuka Morizane, Daisuke Doi, Hiroaki Magotani, Hirotaka Onoe, Takuya Hayashi, Hiroshi Mizuma, Sayuki Takara, Ryosuke Takahashi, Haruhisa Inoue, Satoshi Morita, Michio Yamamoto, Keisuke Okita, Masato Nakagawa, Malin Parmar, Jun TakahashiHuman iPS cell-derived dopaminergic neurons function in a primate Parkinsons disease modelNature, 2017; 548 (7669): 592 DOI: 10.1038/nature23664

Image: Annie Cavanagh / Wellcome Images

Visit link:
iPS Cell-based Neuron Therapy Benefits Monkeys With Parkinson's - ReliaWire

Policy addresses therapeutic use of stem cells, regenerative medicine – American Veterinary Medical Association

Posted Aug. 30, 2017

The AVMA House of Delegates passed a new policy July 21 on "Therapeutic Use of Stem Cells and Regenerative Medicine."

According to the policy: "Regenerative medicine is defined as the use of biological therapies including platelet rich-plasma, pluripotent stem cells, and multipotent stem cells to effect therapeutic benefit in disease states. While regenerative medicine holds promise of improvements in the treatment of a variety of diseases, many of which lack adequately effective treatments, questions remain. The AVMA supports the continued scientific development of these modalities while at the same time encouraging its members to employ caution with respect to their use.

"While data continue to accumulate suggesting therapeutic benefit from regenerative medicine, published peer-reviewed studies definitively documenting benefit are still lacking for many diseases. Nor has a scientific consensus for stem cell type, stem cell origin, dosage, transfer media, or method of administration been developed for each disease being treated. Despite these scientific insufficiencies, the adoption of regenerative medicine in the veterinary profession has grown rapidly. Unfortunately, some therapies being propounded and the processes and equipment being sold have outpaced the science which supports them. Veterinarians have few guidelines and limited resources for differentiating valid and effective therapies from ones which have insufficient data supporting the processes and/or therapies. Therefore, it is incumbent upon veterinarians engaged in regenerative therapies to be well versed in the emerging science of the field in order to successfully select the specific therapeutic protocols, processes, equipment, and vendors most likely to result in clinical benefit for their patients."

The policy lists nine considerations for use of regenerative medicine by veterinarians.

AVMA to deliberate on assistance animals, stem cells (June 1, 2017)

FDA finalizes guidance on cell-based products in animals (July 15, 2015)

Stem cells in theory & practice (Feb. 15, 2011)

Follow this link:
Policy addresses therapeutic use of stem cells, regenerative medicine - American Veterinary Medical Association

Monkeys With Parkinson’s Disease Successfully Treated With Human Stem Cell Transplants – Technology Networks

Monkeys show reduced Parkinsonian symptoms following a donor-matched iPS cell-based therapy. Misaki Ouchida, Center for iPS Cell Research and Application, Kyoto University

One of the last steps before treating patients with an experimental cell therapy for the brain is confirmation that the therapy works in monkeys. In its latest study, the Jun Takahashi lab shows monkeys with Parkinson's disease symptoms show significant improvement over two years after being transplanted neurons prepared from human iPS cells. The study, which can be read in Nature, is expected to be a final step before the first iPS cell-based therapy for a neurodegenerative disease.

Parkinson's disease degenerates a specific type of cells in the brain known as dopaminergic (DA) neurons. It has been reported that when symptoms are first detected, a patient will have already lost more than half of his or her DA neurons. Several studies have shown the transplantation of DA neurons made from fetal cells can mitigate the disease. The use of fetal tissues is controversial, however. On the other hand, iPS cells can be made from blood or skin, which is why Professor Takahashi, who is also a neurosurgeon specializing in Parkinson's disease, plans to use DA neurons made from iPS cells to treat patients.

"Our research has shown that DA neurons made from iPS cells are just as good as DA neurons made from fetal midbrain. Because iPS cells are easy to obtain, we can standardize them to only use the best iPS cells for therapy, " he said.

To test the safety and effectiveness of DA neurons made from human iPS cells, Tetsuhiro Kikuchi, a neurosurgeon working in the Takahashi lab, transplanted the cells into the brains of monkeys.

"We made DA neurons from different iPS cells lines. Some were made with iPS cells from healthy donors. Others were made from Parkinson's disease patients," said Kikuchi, who added that the differentiation method used to convert iPS cells into neurons is suitable for clinical trials.

It is generally assumed that the outcome of a cell therapy will depend on the number of transplanted cells that survived, but Kikuchi found this was not the case. More important than the number of cells was the quality of the cells.

"Each animal received cells prepared from a different iPS cell donor. We found the quality of donor cells had a large effect on the DA neuron survival," Kikuchi said.

To understand why, he looked for genes that showed different expression levels, finding 11 genes that could mark the quality of the progenitors. One of those genes was Dlk1.

"Dlk1 is one of the predictive markers of cell quality for DA neurons made from embryonic stem cells and transplanted into rat. We found Dlk1 in DA neurons transplanted into monkey. We are investigating Dlk1 to evaluate the quality of the cells for clinical applications."

Another feature of the study that is expected to extend to clinical study is the method used to evaluate cell survival in the host brains. The study demonstrated that magnetic resonance imaging (MRI) and position electron tomography (PET) are options for evaluating the patient post surgery.

"MRI and PET are non-invasive imaging modalities. Following cell transplantation, we must regularly observe the patient. A non-invasive method is preferred," said Takahashi.

The group is hopeful that it can begin recruiting patients for this iPS cell-based therapy before the end of next year. "This study is our answer to bring iPS cells to clinical settings," said Takahashi.

This article has been republished frommaterialsprovided byCIRA, Kyoto University. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Monkeys With Parkinson's Disease Successfully Treated With Human Stem Cell Transplants - Technology Networks

Monkeys with Parkinson’s disease benefit from human stem cells – Medical Xpress

Monkeys show reduced Parkinsonian symptoms following a donor-matched iPS cell-based therapy. Credit: Misaki Ouchida, Center for iPS Cell Research and Application, Kyoto University

One of the last steps before treating patients with an experimental cell therapy for the brain is confirmation that the therapy works in monkeys. Today, scientists at the Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, report monkeys with Parkinson's disease symptoms show significant improvement over two years after being transplanted neurons prepared from human iPS cells. The study, which can be read in Nature, is an expected final step before the first iPS cell-based therapy for neurodegenerative diseases.

Parkinson's disease degenerates a specific type of cells in the brain known as dopaminergic (DA) neurons. It has been reported that when symptoms are first detected, a patient will have already lost more than half of his or her DA neurons. Several studies have shown the transplantation of DA neurons made from fetal cells can mitigate the disease. The use of fetal tissues is controversial, however. On the other hand, iPS cells can be made from blood or skin, which is why Professor Takahashi, who is also a neurosurgeon specializing in Parkinson's disease, plans to use DA neurons made from iPS cells to treat patients.

"Our research has shown that DA neurons made from iPS cells are just as good as DA neurons made from fetal midbrain. Because iPS cells are easy to obtain, we can standardize them to only use the best iPS cells for therapy, " he said.

To test the safety and effectiveness of DA neurons made from human iPS cells, Tetsuhiro Kikuchi, a neurosurgeon working in the Takahashi lab, transplanted the cells into the brains of monkeys.

"We made DA neurons from different iPS cells lines. Some were made with iPS cells from healthy donors. Others were made from Parkinson's disease patients," said Kikuchi, who added that the differentiation method used to convert iPS cells into neurons is suitable for clinical trials.

It is generally assumed that the outcome of a cell therapy will depend on the number of transplanted cells that survive, but Kikuchi found this was not the case. More important than the number of cells was the quality of the cells.

"Each animal received cells prepared from a different iPS cell donor. We found the quality of donor cells had a large effect on the DA neuron survival," Kikuchi said.

To understand why, he looked for genes that showed different expression levels, finding 11 genes that could mark the quality of the progenitors. One of those genes was Dlk1.

"Dlk1 is one of the predictive markers of cell quality for DA neurons made from embryonic stem cells and transplanted into rat. We found Dlk1 in DA neurons transplanted into monkey. We are investigating Dlk1 to evaluate the quality of the cells for clinical applications."

Another feature of the study that is expected to extend to clinical study is the method used to evaluate cell survival in the host brains. The study demonstrated that magnetic resonance imaging (MRI) and position electron tomography (PET) are options for evaluating the patient post surgery.

"MRI and PET are non-invasive imaging modalities. Following cell transplantation, we must regularly observe the patient. A non-invasive method is preferred," said Takahashi.

The group is hopeful that it can begin recruiting patients for this iPS cell-based therapy before the end of next year. "This study is our answer to bring iPS cells to clinical settings," said Takahashi.

Explore further: Conversion of brain cells offers hope for Parkinson's patients

More information: Tetsuhiro Kikuchi et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model, Nature (2017). DOI: 10.1038/nature23664

Journal reference: Nature

Provided by: Kyoto University

See original here:
Monkeys with Parkinson's disease benefit from human stem cells - Medical Xpress

Puppies receive stem cell treatment developed to help children with spina bifida – Sacramento Bee

A procedure combining surgery with stem cell treatment has aided two bulldog puppies with spina bifida and a team of UC Davis researchers hopes to test the therapy in human clinical trials.

The puppies were treated with a therapy developed at UC Davis to help preserve lower-limb function in children with spina bifida, according to a university news release.

Spina bifida occurs when spinal tissue improperly fuses in utero causing cognitive, mobility, urinary and bowel disabilities. Approximately 1,500 to 2,000 children in the United States are born with the condition each year.

Because dogs with the birth defect have little control of their hindquarters, they typically are euthanized as puppies.

After their post-surgery checkup at 4 months old, the sibling pups, Darla and Spanky, showed off their ability to walk, run and play.

The initial results of the surgery are promising, as far as hind limb control, veterinary neurosurgeon Beverly Sturges said in a written statement. Both dogs seemed to have improved range of motion and control of their limbs.

The dogs have since been adopted and continue to do well at home in New Mexico.

The dogs procedure involved surgical techniques developed by fetal surgeon Diana Farmer of UC Davis Health together with a cellular treatment developed by stem cell scientists Aijun Wang and Dori Borjesson, director of the universitys Veterinary Institute for Regenerative Cures.

Farmer pioneered the use of surgery prior to birth to improve brain development in children with spina bifida. She later showed that prenatal surgery combined with cells derived from the human placenta held in place with a cellular scaffold helped research lambs born with the disorder walk without noticeable disability, the news release said.

Sturges wanted to find out whether the surgery-plus-stem-cell approach could give dogs more normal lives, as well as better chances of survival and adoption.

Darla and Spanky were transported from Southern California Bulldog Rescue to the UC Davis Veterinary hospital when they were 10 weeks old. They were the first dogs to receive the treatment, this time using canine instead of human placenta-derived cells.

The dogs treatment also occurred after birth, because the prenatal diagnosis of spina bifida is not performed on dogs, Sturges said. The disorder becomes apparent between 1 and 2 weeks of ages, when puppies show hind-end weakness, poor muscle tone and abnormal use of their tails.

The research team wants dog breeders to send more puppies with spina bifida to UC Davis for treatment and refinements that will help researchers correct another hallmark of spina bifida, incontinence. Although Darla and Spanky are mobile and doing well, they still require diapers, the news release said.

Read this article:
Puppies receive stem cell treatment developed to help children with spina bifida - Sacramento Bee

Terre Haute animal hospital in stem cell study for dogs – WISH-TV

Deana ReecePublished: August 23, 2017, 7:22 pmUpdated: August 23, 2017, 9:34 pm

TERRE HAUTE, Ind. (WTWO) Maggie Mae and her owner, Robert Howrey, came from Paris, Illinois, for a check-up at the Wabash Valley Animal Hospital in Terre Haute.

She doesnt act like it, but Maggie Mae is a senior citizen and she has problems with her joints.

Arthritis is a common condition in older dogs and we like to help them out, said Dr. Andrew Pickering, a local veterinarian.

A California company called Animal Cell Therapies has enlisted U.S. veterinarians to participate in a study of using stem cells for dogs with arthritis. Some of the canines in the study receive an injection of stem cells, others get just a saline solution.

Pickering doesnt know which injections Maggie Mae is getting, but she no longer limps. Hes encouraged by the results.

Were hoping this particular type of treatment will cure the condition for a long period of time so we dont have to keep giving the dog medication all the time, Pickering said.

Howrey said its almost like having a new dog.

Its been about six weeks, so now shes back doing normal activities, she runs, she chases squirrels.

The research will continue for several more months. The local clinic is looking for owners who would like to involve their pets. Study participation is free for dogs that qualify. Plus, even the animals that receive the saline injections can get the stem cell treatment once the study is complete.

Like Loading...

Read more here:
Terre Haute animal hospital in stem cell study for dogs - WISH-TV

Veterinary Growth Partners Selects MediVet Biologics as Preferred Vendor for Veterinary Biologics – Benzinga

Stem Cell and other innovative biologic pet treatments now available medically to broad base of progressive veterinarians.

(PRWEB) August 24, 2017

Veterinary Growth Partners (VGP), a veterinary membership group with over 4,000 independent veterinary hospital members, helps practices accelerate their goals, growth and business success. VGP offers its members numerous benefits including preferred pricing, dedicated practice coaches, robust education for various job roles in the hospital, marketing tools, and some of the most impressive practice management tools in the industry. VGP has selected MediVet Biologics as a preferred vendor to provide its member hospitals access to innovative biologic treatments including advanced Stem Cell and Platelet Rich Plasma therapies for degenerative diseases in animals.

To date, over 12,000 animals have been treated with MediVet Biologics ActiStem stem cell treatment. ActiStem is the only US based animal stem cell treatment to be tested in a university randomized, double blind, placebo controlled trial.

In addition to regenerative medicine, Veterinary Growth Partners clinics will have access to K9-ACV, an immunotherapy vaccine designed to be an affordable option for canine cancer. The two organizations will provide education to the network of progressive veterinarians via innovative labs and learning experiences.

This signifies a continued shifting dynamic in pet healthcare with a focus on personalized and innovative medical treatment options being sought out for pets. Robert Sigman, CEO of VGP said, "Veterinary Growth Partners is excited to partner with MediVet Biologics. We strive to bring the best products and services in our industry to members at significant savings. MediVet's products are best in class. We look forward to working with them for many years to come."

"Pets are family members and their human families demand access to the same innovations and quality of care available in human medicine. We are here in the marketplace to provide our veterinary customers those options. Our partnership with VGP will continue to assist us in driving our mission to assist millions of animals across the globe", said Jeff Baker President of MediVet Biologics.

About MediVet BiologicsMediVet Biologics is a global leader in innovative medical solutions for the animal health market. The company has a portfolio of products and services to include regenerative medicine and immunotherapy for canine cancer. For more information please visit: http://www.medivetbiologics.com

About Veterinary Growth PartnersVeterinary Growth Partners is a membership organization for innovative veterinary practices. We bring you tools, templates, and cost-saving programs to grow your profit. To learn more about VGP, please visit: http://www.vgpvet.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14629431.htm

The rest is here:
Veterinary Growth Partners Selects MediVet Biologics as Preferred Vendor for Veterinary Biologics - Benzinga

Cellectar Biosciences Inc (NASDAQ:CLRB) Pops Higher on Strong Research Data – The Oracle Dispatch

Cellectar Biosciences Inc (NASDAQ:CLRB)is a pharmaceutical stock thats popping up on everyones radar. This week has been an criticalweek for CLRB, as it blasted higher out of a key low consolidation on a strong jump in volume. The catalyst appears to be the CLRBs announcement this week that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significantly improved pharmacologic activity versus the payload molecule alone.

According to the release, utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the companys PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.

Cellectar Biosciences Inc (NASDAQ:CLRB) bills itself as a company developing agents to detect, treat and monitor a broad spectrum of cancers.

Utilizing a novel phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, CLRBs compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.

A Phase II trial evaluating I-124-CLR1404 in glioblastoma is expected to be completed in 2014. Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

CLRB was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Find outwhen $CLRB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, CLRB just popped off a key technical low on the companys announcement that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that apparently show significant improved pharmacologic activity versus the payload molecule alone. That could be huge news for the company.

The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform, said Jim Caruso, president and CEO of Cellectar Biosciences. We continue to drive our key internal programs in a strategic and cost-efficient manner including the advancement of candidate molecules from these new compound series. The company anticipates sharing additional technical details of this work either in peer reviewed journal articles or at a future oncology conference.

Recent action has seen 15% piled on for shareholders of the company during the trailing week, a bounce that has taken root amid largely bearish action over the larger time frame. Market participants may want to pay attention to this stock. CLRB is a stock whose past is littered with sudden rips. Whats more, the listing has seen interest climb, with an increase in recent trading volume of just shy of 150% over what the stock has registered over the longer term.

Earning a current market cap value of $24.92M, CLRBhas a significant war chest ($8.4M) of cash on the books, which is balanced by virtually no total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire.For continuing coverage on shares of $CLRB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakoutpick!

Disclosure: We hold no position in $CLRB, either long or short, and we have not been compensated for this article.

See the original post:
Cellectar Biosciences Inc (NASDAQ:CLRB) Pops Higher on Strong Research Data - The Oracle Dispatch

Stem cells could benefit cockapoo’s knee issue – Albuquerque Journal

.......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........

Dr. Nichol: If your cockapoo has somewhat bowed rear legs, one or both of her knee caps (patellas) may slip out of its groove at the lower end of her thigh bone. Some patellas dislocate (luxate) just occasionally. A dog may skip for a few steps and then use the leg normally again after the patella slips back into the groove.

The knees of a dog with luxating patellas are vulnerable to injury. Your girls missed jump may have strained the supportive tendons that guide her patella. Rest and anti-inflammatory medication can help in the short term but the anatomy would still be structurally unsound. The only permanent solution will be surgical remodeling of the attachment of her patella and the groove in her lower femur.

Called a tibial crest rotation this surgery is a long-established procedure that many veterinarians are skilled at performing. But even with the geometric forces corrected, some chronic damage to a dogs tendons and cartilage will remain. Thats what makes stem cell therapy valuable.

While your girl is under anesthesia for knee surgery her doctor can make a small abdominal incision and remove a bit of fat. Your dogs very own stem cells (no risk of rejection) will be processed and shipped back overnight for injection into her knee. Over the following weeks the stem cells will stimulate regeneration of chronically inflamed tissues, resulting in a stronger and more comfortable joint.

Finally, stem cell therapy, also known as regenerative medicine, is not new. Veterinary orthopedists have used stem cells for 15 years to speed healing and reach better long-term outcomes.

Each week I make a short video or podcast to help bring out the best in pets. Sign up at no charge on my website, drjeffnichol.com. Every Tuesday it will arrive in your email. Ill also send you my free Pet Emergency and CPR guide.

Dr. Jeff Nichol treats behavior disorders at the Veterinary Emergency & Specialty Centers in Albuquerque and Santa Fe (505-792-5131). Questions on pet behavioral or physical concerns? For answers, Like my Facebook page at facebook.com/drjeffnichol or by mail to 4000 Montgomery NE, Albuquerque, NM 87109.

Excerpt from:
Stem cells could benefit cockapoo's knee issue - Albuquerque Journal

IN-DEPTH: Fighting for your life – Leavenworth Times

Julie Gould was heartbroken to learn that there was no cure for diffuse scleroderma, the chronic disease that she was diagnosed with in 2016.

Julie Gould was heartbroken to learn that there was no cure for diffuse scleroderma, the chronic disease that she was diagnosed with in 2016.The life-threatening auto-immune disease affects connective tissue in the body by producing too much collagen and hardening cartilage, tendons and skin.

I was depressed when I received the initial diagnosis, she said. It's difficult to hear that you may be dead in five years time. According to the Scleroderma Foundation, A person newly diagnosed with scleroderma may feel alone and uncertain about where to turn for help. He or she may experience a number of other feelings and emotional reactions from time to time, including initial shock or disbelief, fear, anger, denial, self-blame, guilt, grief, sadness or depression. Family members may have similar feelings.

When Julie first consulted a doctor in 2015, she was concerned that she might have picked up an infectious disease, such as a mosquito-born illness, or as she described it, the worst flu ever, during a vacation to Mexico. But she was told that diabetic neuropathy was causing the pins and needles tingling in her hands and feet.

My hands and feet continued to swell and I thought I had heart failure, said Julie. I went to a cardiologist to see if that was the problem. Those tests and lab work came back normal too.When the pain and swelling became excruciating, she consulted with a rheumatologist. When diabetic neuropathy was ruled out, she was told it could be rheumatoid arthritis. Although the lab tests were within normal limits, her doctor thought the labs werent correlating yet because it was so early in diagnosis. She was given medication and told to come back in six weeks, but saw no alleviation of the pain.

When her rheumatologist told her she might have scleroderma and ordered lab work, those tests too were normal.My physical therapist thought I should go to the Mayo Clinic, said Julie. I got online and requested an appointment. Three months later at the clinic in Rochester, Minnesota, she was diagnosed with diffuse scleroderma but it was a rare type that doesnt test positive in the usual lab test. Her total diagnosis wait had been a year and eight months, and she was more than ready to begin treatment. She was given multiple medications for pain and symptom control.After diagnosis, I got online and started searching for information about scleroderma, said Julie. It was dismal. I had to step away from the computer.Current treatments for the disease are varied, but basically treat the organs being affected. When lung tissue is hardened, patients are tube-fed and given oxygen. Sometimes lung transplants are required. Some patients need gastrointestinal surgery and some have operations to decrease ulcers on their fingers, while some must have their fingers and toes amputated.

Medication for high blood pressure and chemotherapy to suppress the disease are common with the disease and stiff joints and skin can result in patients not being able to stand upright and wheelchair-bound. Physical and occupational therapy is required to save body functions.Julies mother and sister, who is a nurse, also began scouring the internet for treatments. When they read about stem cell transplant they both felt this was the answer to Julies prayers.

Overcome with depression and pain, Julie began taking an antidepressant. With the help of the drug and limitless help and support from her family, the research on transplant gave her much needed hope. When I found out about the transplant, I was scared, said Julie. I feared for my life being taken by this disease.

This disease literally affects every organ system in the body. Transplant offered a chance to stop the disease in its tracks and stop further progression and damage to my body. I had been recently diagnosed, so the doctor said I could wait until I was worse, then have the transplant at a later date. I did not wait. I already had heart, lung, GI, and musculoskeletal systems involved. This approach was proactive, not reactive. It offered me hope.To qualify for stem cell treatment a patient must be sick enough toneed it, but not so sick that they would not benefit from the procedure.

We were able to find many groups to help us learn about scleroderma, she said. Inspire and Facebook were invaluable. There were specific groups for people who had scleroderma. Groups for people who needed a stem cell transplant. Groups for people with scleroderma, who wanted, or who already had a transplant.I started to read all the testimonials. I looked at the NIH website. This was productive research. I was finding out information on how to save my life not on how I was going to die.

After Julie applied for evaluation by Dr. Richard Burt at Northwestern in Chicago, she had scores of tests, including a CT scan of her lungs, MRI of her chest, EKG, sonogram of her heart, heart cath, colonoscopy, EGD, lab work, stress tests, psychological exam, dental exam, and 24-hour urine collection.

After all the anxious waiting during almost two years of doctor visits and tests, Julie was informed that she had passed the evaluation and had been approved for stem cell transplant.I came home to mentally prepare myself, said Julie. I returned to Chicago for the mobilization phase. I received a dose of chemo overnight in the hospital to suppress my immune disease. A week later I then started to give myself injections to produce white blood cells using neupogen. This medication forces the bone marrow to put out extra white blood cells, from which stem cells originate.

After six days of injections, Julie returned to the hospital to have the stem cells removed from her blood for use at a later date. She had to stay in Chicago during this part of treatment in case she had complications from the procedure. The process was similar to dialysis, said Julie. I was at the hospital all day, 12 hours. My own stem cells had been harvested to heal me. After two weeks of rest at home in Leavenworth, Julie returned to Chicago for the transplant. And after five days of more chemo, her stem cells were returned to her body. Now we only had to wait for the transplant to work, said Julie. I stayed in the hospital until the cells engrafted and my immune system started working again. Eight days.I had been in the hospital for 16 days. The transplant is a reboot to your diseased immune system like a reboot to your computer.Julie returned to Leavenworth to rest and recover. My entire family have been tremendously supportive, she said. They offered and provided all of the help that I needed to achieve this treatment.

She is also grateful to the community of Leavenworth for reaching out to help her. They donated money for my out-of-pocket expenses, said Julie. They provided food upon my return from Chicago. I didn't have to cook, nor did my husband for six weeks. Family cleaned my home and watched my children. I was grateful.

Social media also provided support during Julies treatment. She discovered a network of people on Facebook who had already had a transplant, or were waiting to have one. Stem cells are used to treat many auto-immune disorders like multiple sclerosis, lupus, Crohns disease, and many others, said Julie. I could pose any question to this forum and receive an answer. I started my own Facebook page to document my medical treatment so that I too could share my information. It has been wonderful to help others who are experiencing what I have been through.

Julie has just returned from her one-year checkup in Chicago and learned that the progression of the disease has stopped. Stem cell transplant has saved my life, said Julie. I am living, not merely existing.Not only has the disease been stopped in its tracks, Julie has seen physical improvements such as full motion in her shoulder, which was frozen from hardened tissue for much of the last few years. Her contracted hands are also more mobile and she has gained 40 degrees movement in some of her fingers.

I have Raynaud's syndrome, said Julie. It has improved. It was a constant struggle to keep my hands and feet warm. The pain in my hands is mostly gone. The all-over joint pain is gone. The fatigue and malaise are gone. I feel good. I feel happy.As she has regained her back strength and dexterity she is now able to enjoy the routine of normal days, like rising from a chair without pain, sleeping and eating well and even doing simple tasks such as opening a jar, which was difficult after her diagnosis.Everyday tasks were difficult, said Julie. Deodorant, flossing, brushing teeth or hair, dressing. All of the daily activities have gotten easier everyday. The pain is mostly gone.My body feels healthy.

Julie has gained much more than flexibility and relief from constant pain during her long medical challenge, and she emphasizes, I learned to not sweat the small stuff. I learned to live every day. I learned to love every day.

Read more:
IN-DEPTH: Fighting for your life - Leavenworth Times

Back to Top